Why “American Patients First” is likely to raise drug prices outside of the United States

• Main Authors: Monique Dabbous, Cyprien Milea, Steven Simoens, Clement François, Claude Dussart, Lylia Chachoua, Borislav Borissov, Mondher Toumi
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2019-01-01
• Series: Journal of Market Access & Health Policy
• Subjects: drug prices; united states of america (usa); trump; american patients first (apf); free-loading; bilateralism; multilateralism; world trade organization (wto); foreign policy
• Online Access: http://dx.doi.org/10.1080/20016689.2019.1650596

Background: The Trump administration’s ‘American Patients First’ blueprint proposes to reduce drug prices in the USA by increasing drug prices abroad, ex USA. The possibility of the Trump administration to raise drug prices ex USA through legal action via the WTO and bilateral negotiations with foreign trade partners was reviewed. Methods: A literature review was conducted through PUBMED, EMBASE, Media and grey literature to consolidate publications of the Trump administrations’ policies and strategies towards foreign countries and drug prices. Results: The Trump administration has withdrawn from and halted major multilateral agreements including the TPP, Paris Agreement, TTIP, UNESCO, NAFTA (now USMCA), and NATO. The Trump administration has been successful in bilateral negotiations for pharmaceuticals’ pricing, as seen with Japan, South Korea, Germany, and Mexico and Canada. Conclusion: The objective of raising prices abroad is attainable. Action through the WTO is unlikely, due to its nondiscriminatory principle. Bilateral trade negotiation have proven more promising. In this bilateral framework, financial security and military protection are strong assets for the USA to levy higher drug prices abroad. Although raising drug prices ex USA is possible, further questions as to whether this will directly translate into lower drug prices for American patients are raised.